191 related articles for article (PubMed ID: 12366465)
1. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations.
Freudenreich O; Goff DC
Acta Psychiatr Scand; 2002 Nov; 106(5):323-30. PubMed ID: 12366465
[TBL] [Abstract][Full Text] [Related]
2. Risperidone augmentation of clozapine: a critical review.
Kontaxakis VP; Ferentinos PP; Havaki-Kontaxaki BJ; Paplos KG; Pappa DA; Christodoulou GN
Eur Arch Psychiatry Clin Neurosci; 2006 Sep; 256(6):350-5. PubMed ID: 16900439
[TBL] [Abstract][Full Text] [Related]
3. Review: Combination therapy with non-clozapine atypical antipsychotic medication: a review of current evidence.
Chan J; Sweeting M
J Psychopharmacol; 2007 Aug; 21(6):657-64. PubMed ID: 17092976
[TBL] [Abstract][Full Text] [Related]
4. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
5. Clozapine versus risperidone in treatment-refractory schizophrenia: possible impact of dosing strategies.
Lane HY; Chang WH
J Clin Psychiatry; 1999 Jul; 60(7):487-8. PubMed ID: 10453806
[No Abstract] [Full Text] [Related]
6. Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis.
Smith RC; Leucht S; Davis JM
Psychopharmacology (Berl); 2019 Feb; 236(2):545-559. PubMed ID: 30506237
[TBL] [Abstract][Full Text] [Related]
7. The combined use of risperidone long-acting injection and clozapine in patients with schizophrenia non-adherent to clozapine: a case series.
Se Hyun Kim ; Dong Chung Jung ; Yong Min Ahn ; Yong Sik Kim
J Psychopharmacol; 2010 Jul; 24(7):981-6. PubMed ID: 19942641
[TBL] [Abstract][Full Text] [Related]
8. Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial.
Freudenreich O; Henderson DC; Walsh JP; Culhane MA; Goff DC
Schizophr Res; 2007 May; 92(1-3):90-4. PubMed ID: 17321111
[TBL] [Abstract][Full Text] [Related]
9. Risperidone versus other atypical antipsychotic medication for schizophrenia.
Gilbody SM; Bagnall AM; Duggan L; Tuunainen A
Cochrane Database Syst Rev; 2000; (3):CD002306. PubMed ID: 10908551
[TBL] [Abstract][Full Text] [Related]
10. Clozapine augmentation: safety and efficacy.
Chong SA; Remington G
Schizophr Bull; 2000; 26(2):421-40. PubMed ID: 10885641
[TBL] [Abstract][Full Text] [Related]
11. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of atypical antipsychotics in chronic schizophrenia.
Amin S
Hosp Med; 1999 Jun; 60(6):410-3. PubMed ID: 10492711
[TBL] [Abstract][Full Text] [Related]
13. Measuring outcome in schizophrenia: differences among the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.
J Clin Psychiatry; 1998; 59 Suppl 12():3-9. PubMed ID: 9766613
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial.
Zink M; Kuwilsky A; Krumm B; Dressing H
J Psychopharmacol; 2009 May; 23(3):305-14. PubMed ID: 18562423
[TBL] [Abstract][Full Text] [Related]
15. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
Tauscher J; Hussain T; Agid O; Verhoeff NP; Wilson AA; Houle S; Remington G; Zipursky RB; Kapur S
Am J Psychiatry; 2004 Sep; 161(9):1620-5. PubMed ID: 15337652
[TBL] [Abstract][Full Text] [Related]
16. Combination antipsychotics: pros, cons, and questions.
Miller AL; Craig CS
Schizophr Bull; 2002; 28(1):105-9. PubMed ID: 12047009
[TBL] [Abstract][Full Text] [Related]
17. Combination of "atypical" antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder.
Lerner V; Libov I; Kotler M; Strous RD
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):89-98. PubMed ID: 14687862
[TBL] [Abstract][Full Text] [Related]
18. Quetiapine versus other atypical antipsychotics for schizophrenia.
Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
[TBL] [Abstract][Full Text] [Related]
19. Clinical trial-based cost-effectiveness analyses of antipsychotic use.
Polsky D; Doshi JA; Bauer MS; Glick HA
Am J Psychiatry; 2006 Dec; 163(12):2047-56. PubMed ID: 17151153
[TBL] [Abstract][Full Text] [Related]
20. The impact of atypical antipsychotic medications on the use of health care by patients with schizophrenia.
Chen L; McCombs JS; Park J
Value Health; 2008; 11(1):34-43. PubMed ID: 18237358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
